Loading insider details...
Beta
Latest Form 4 (Oct 16, 2026): Exercise/Conversion of 30,000 CRSP shares, $420.0K.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Oct 16, 2026 | CRISPR Therapeutics AG (CRSP) | Exercise/Conversion | 30,000 | $420.0K |
| Sep 30, 2026 | ADARx Pharmaceuticals, Inc. (ADRX) | Conversion | 3,334,938 | n/a |
| Jun 11, 2026 | Design Therapeutics, Inc. (DSGN) | Grant/Award | 30,000 | n/a |
| Jun 11, 2026 | Nkarta, Inc. (NKTX) | Grant/Award | 37,000 | n/a |
| Jun 9, 2026 | CRISPR Therapeutics AG (CRSP) | Grant/Award | 13,000 | n/a |
| May 12, 2026 | Odyssey Therapeutics, Inc. (ODTX) | Conversion | 474,048 | n/a |
| May 1, 2026 | Avalyn Pharma Inc. (AVLN) | Conversion | 1,419,298 | n/a |
| Oct 14, 2025 | Zenas BioPharma, Inc. (ZBIO) | Purchase | 63,158 | $1.20M |
| Jul 17, 2025 | CRISPR Therapeutics AG (CRSP) | Purchase | 6,510 | $338.7K |
| Jun 12, 2025 | Design Therapeutics, Inc. (DSGN) | Grant/Award | 19,000 | n/a |